Dr. Matt Kaeberlein to present at the 6th Aging Research for Drug Discovery Forum Basel

IMAGE

Credit: Insilico Medicine

Monday, March 11, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, announces the presentation of Matt Kaeberlein, Ph.D., Department of Pathology, University of Washington, at 6th Aging Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019, Basel, Switzerland.

Advances in geroscience are allowing scientists and clinicians, for the first time, to consider interventions aimed at directly targeting the hallmarks of aging. Unlike disease-specific approaches, such interventions have the potential to prevent multiple diseases of aging simultaneously, thereby greatly enhancing healthspan for most individuals. Drugs that inhibit the mTOR pathway, such as rapamycin, are currently among the leading candidates for delaying aging in humans and companion animals. The presentation will focus on recent progress on preclinical and clinical application of mTOR inhibitors to slow aging and maximize healthy longevity.

“It’s an exciting time for the field. We’ve made great progress in understanding the biological mechanisms of aging, and now, for the first time, we are starting to see clinical application of these discoveries. Unlike traditional medical approaches, which wait until people are sick before trying to “cure” their disease, 21st Century Medicine involves targeting aging directly in order to keep people healthy much longer and later into life,” said Matt Kaeberlein, Ph.D., Department of Pathology, University of Washington.

“Over the last 5 years, the “Aging & Drug Discovery” and “AI for Healthcare” forums have been leading events at BaselLife, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled “the 6th Aging, AI and Drug Discovery Forum” to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet,” said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.

“The 6th annual Aging Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in aging and longevity research covering the theory, applications and convergence of these three exciting areas,” – said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.

The 6th Aging Research for Drug Discovery Forum Basel will bring together leaders in the aging, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. The Forum will be held in Basel, Switzerland, September 9-12, 2019.

###

Contact: Ola Popova

ola@pharma.ai

Website: http://insilico.com/

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

About Basel Life 2019

Forum description:

In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet.

Conference Official Website : https://www.basellife.org/2019.html

About the University of Washington

Founded 4 November 1861, the University of Washington is one of the oldest state-supported institutions of higher education on the Pacific coast. The primary mission of the University of Washington is the preservation, advancement, and dissemination of knowledge. The University preserves knowledge through its libraries and collections, its courses, and the scholarship of its faculty. The University fosters an environment in which its students can develop mature and independent judgment and an appreciation of the range and diversity of human achievement. The University cultivates in its students both critical thinking and the effective articulation of that thinking.

University Website: http://www.washington.edu/

About the University of Copenhagen

With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University – to quote the University Statute – is to ‘conduct research and provide further education to the highest academic level’. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.

University Website: http://introduction.ku.dk/presentation/

Media Contact
Ola Popova
ola@pharma.ai

Comments